Polyphenols from Lonicera caerulea L. Berry ... - ACS Publications

Subscriber access provided by Binghamton University | Libraries

Article

Polyphenols from Lonicera caerulea L. Berry Inhibit LPS-induced Inflammation through Dual Modulation of Inflammatory and Antioxidant Mediators Shusong Wu, Satoshi Yano, Jihua Chen, Ayami Hisanaga, Kozue Sakao, Xi He, Jianhua He, and De-Xing Hou J. Agric. Food Chem., Just Accepted Manuscript • DOI: 10.1021/acs.jafc.7b01599 • Publication Date (Web): 02 Jun 2017 Downloaded from http://pubs.acs.org on June 9, 2017

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Journal of Agricultural and Food Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 44

Journal of Agricultural and Food Chemistry

1

Title

Polyphenols from Lonicera caerulea L. Berry Inhibit LPS-induced Inflammation

2 3

through Dual Modulation of Inflammatory and Antioxidant Mediators Running Title

Dual Modulation of Inflammatory and Antioxidant Mediators by Lonicera

4

caerulea L. Berry Polyphenols

5 6

Shusong Wua, Satoshi Yanob, Jihua Chenc, Ayami Hisanagab, Kozue Sakaob,d,

Authors

Xi Hea, Jianhua Hea, De-Xing Houa,b,d*

7 8 9

Affiliations:

a

Core Research Program 1515, Hunan Collaborative Innovation Center for

10

Utilization of Botanical Functional Ingredients, Hunan Agricultural University,

11

Changsha, Hunan 410128, China b

12

The United Graduate School of Agricultural Sciences, Kagoshima University,

13

Korimoto 1-21-24, Kagoshima 890-0065, Japan c

14

Department of Nutrition Science and Food Hygiene, XiangYa School of Public

15

Health, Central South University, Changsha, Hunan 410078, China d

16 17

Department of Food Science and Biotechnology, Faculty of Agriculture, Kagoshima University, Korimoto 1-21-24, Kagoshima 890-0065, Japan

18 19



Corresponding author: Professor De-Xing Hou, Department of Food Science and

20

Biotechnology, Faculty of Agriculture, Kagoshima University, Korimoto 1-21-24, Kagoshima

21

890-0065, Japan

22

E-mail: [email protected] (DX. Hou). Tel/Fax: +81-99-285-8649.

ACS Paragon Plus Environment


23

Abstract

24

Lonicera caerulea L. berry polyphenols (LCBP) are considered as major components for the

25

bioactivities. This study aimed to clarify the molecular mechanisms by monitoring inflammatory

26

and antioxidant mediator actions in lipopolysaccharide (LPS)-induced mouse paw edema and

27

macrophage cell model. LCBP significantly attenuated LPS-induced paw edema (3.0 ± 0.1 to 2.8

28

± 0.1 mm, P < 0.05) and reduced (P < 0.05) serum levels of monocytes chemotactic protein-1

29

(MCP-1, 100.9 ± 2.3 to 58.3 ± 14.5 ng/ml), interleukin (IL)-10 (1596.1 ± 424.3 to 709.7 ± 65.7

30

pg/ml), macrophage inflammatory protein (MIP)-1α (1761.9 ±208.3 to 1369.1 ±56.4 pg/ml), IL-6

31

(1262.8 ±71.7 to 499.0 ±67.1 pg/ml), IL-4 (93.3 ±25.7 to 50.7 ±12.5 pg/ml), IL-12(p-70) (580.4

32

±132.0 to 315.2 ±35.1 pg/ml), tumor necrosis factor-α (TNF-α, 2045.5 ±264.9 to 1270.7 ±158.6

33

pg/ml). Cell signaling analysis revealed that LCBP inhibited transforming growth factor β

34

activated kinase-1 (TAK1)-mediated mitogen-activated protein kinase (MAPK) and nuclear

35

factor-κB (NF-κB) pathways, and enhanced the expression of nuclear factor (erythroid-derived

36

2)-like 2 (Nrf2) and manganese-dependent superoxide dismutase (MnSOD) in earlier response.

37

Moreover, cyanidin 3-glucoside (C3G) and (-)epicatechin (EC), two major components of LCBP,

38

directly bound to TAK1. These data demonstrated that LCBP might inhibit LPS-induced

39

inflammation by modulating both inflammatory and antioxidant mediators.

40 41

Keywords: Lonicera caerulea L.; Polyphenol; Anti-inflammatory; Antioxidant; Cytokines

42 43 44


Page 2 of 44

Page 3 of 44

45


1. Introduction

46

Lonicera caerulea L., commonly known as blue honeysuckle or haskap, is a member of the

47

Caprifoliaceae family growing natively in Hokkaido of Japan, Siberia of Russia, and northern

48

China. Its berry has been reported to possess multiple bioactivities such as anti-microbial1,

49

antioxidant2, and anti-inflammatory3. Lonicera caerulea L. berry polyphenols (LCBP) are

50

considered to be the major components on these bioactivities. Our recent studies revealed that

51

LCBP could inhibit adjuvant-induced arthritis4 and high fat dietary/stress-induced nonalcoholic

52

steatohepatitis5 with enhanced expression of antioxidant mediators and decreased expression of

53

inflammatory mediators. Thus, we speculated that LCBP possibly inhibit the inflammation

54

through dual modulation of inflammatory and antioxidant mediators although the mechanisms that

55

how and what kind of mediators LCBP modulate remain unclear.

56

Although inflammatory processes are complicated, cytokines such as interleukins,

57

chemokines, interferons, and tumor necrosis factors secreted by immune cells are critical

58

mediators for inflammatory response6. The release of inflammatory cytokines into circulation can

59

induce the recruitment of immune cells such as macrophages to the inflamed tissue to provoke

60

inflammation, and further aggravate systemic inflammation7. Among cellular signaling network in

61

the inflammatory process, mitogen-activated protein kinase (MAPK)8 and nuclear factor-κB

62

(NF-κB)9 cascades are considered as the major pathways that promote the production of

63

inflammatory cytokines. Extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase

64

(JNK), and p38 kinase are the major MAPKs that response to a variety of stimuli in mammalian

65

cells8, 10. NF-κB is bound by IκBs in the cytoplasm, and can be translocated into the nucleus to

66

function as a transcription factor after the proteolytic degradation of IκBs11. The degradation of



67

IκBs is triggered by their phosphorylations12, which are mediated by IκB kinases (IKK)13, 14.

68

Transforming growth factor β activated kinase-1 (TAK1) is an ubiquitin-dependent kinase of IKK,

69

and acts as an upstream regulator of both MAPK and NF-κB pathways15, 16. Lipopolysaccharide

70

(LPS) is the endotoxin produced by all gram-negative bacteria that can induce inflammation by

71

activating immune cells to produce inflammatory cytokines17, and macrophages are considered as

72

the primary cells leading to the production of a variety of inflammatory mediators18.

73

On the other hand, antioxidant mediators play a crucial role in cellular defense system that

74

counteracts the oxidative stress from pro-inflammatory response such as LPS stimulation19.

75

Manganese-dependent superoxide dismutase (MnSOD) is one of the most important antioxidant

76

enzymes to reduce mitochondrial oxidative stress20, and has been proven as the most sensitive

77

antioxidant enzyme response to LPS-induced inflammation21. Nuclear factor (erythroid-derived

78

2)-like 2 (Nrf2) has been identified as a major transcription factor to attenuate LPS-induced

79

inflammatory response by regulating the expression of down-stream antioxidant enzymes19, 22.

80

Therefore, both inflammatory and antioxidant mediators play critical roles in the initiation

81

and progression of inflammation, and have been suggested as potential therapeutic targets of

82

inflammatory diseases23. To clarify the regulatory effects of LCBP on inflammatory and

83

antioxidant mediators, we used both animal and cultural cell models in the present study. First we

84

globally investigated the effects of LCBP on 23 kinds of cytokines in LPS-induced mouse paw

85

edema model, and then identified the regulatory effects of LCBP on the cellular antioxidant and

86

inflammatory mediators in LPS-activated macrophage cell model. Furthermore, we identified the

87

potential target molecule for LCBP bioactive components using ex vivo pull-down assay. Our data

88

demonstrated that LCBP inhibited LPS-induced inflammation through dual modulation of


Page 4 of 44

Page 5 of 44


89

inflammatory and antioxidant mediators by targeting TAK1, a key kinase located on the

90

inflammatory pathway.

91 92

Materials and methods

93

2.1 Chemicals and reagents

94

LPS (Escherichia coli Serotype 055:B5) was purchased from Sigma-Aldrich (Tokyo, Japan).

95

Cyanidin 3-glucoside (C3G, ≥98%) and -(-)epicatechin (EC, ≥98%) from Tokiwa Phytochemical

96

Co., Ltd (Chiba, Japan) were dissolved in DMSO (0.2% final concentration in cultural medium).

97

CNBr-activated Sepharose 4B was from GE Healthcare (Uppsala, Sweden). Antibodies against

98

c-Jun (Ser73), ERK1/2, p38 kinase, JNK1/2, p65, IκB-α, IKKα/β, and TAK1 were purchased from

99

Cell Signaling Technology (Beverly, MA, USA). Antibodies against inducible nitric oxide

100

synthases (iNOS), MnSOD, Nrf2, 70-kDa heat shock protein (HSP70), α-tubulin (B-7), lamin B,

101

and corresponding secondary antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA,

102

USA). LCBP was extracted as described in our previous study4. In brief, Lonicera caerulea L.

103

berries harvested in Jilin region of China were homogenized in 75% aqueous ethanol (250 g/l) for

104

60 min, and then filtered under reduced pressure. The filtrates were applied on a column packed

105

with nonionic polystyrene-divinylbenzene resin (D101, Shanghai, China). The column was first

106

washed with deionized water, and then eluted by 75% ethanol. The eluates containing phenolic

107

compounds were evaporated at 30 ℃ until no alcohol remained, and then freeze-dried into powder

108

at -20 ℃. The phenolic fraction obtained was analyzed by HPLC at 280 and 520 nm. According to

109

the peak areas in the retention profiles identified by standard samples, C3G (59.5%) and EC

110

(25.5%) were identified as the major phenolic components at 280 nm while other minor



111

anthocyanins including peonidin 3-glucoside (7.2%), pelargonidin 3-glucoside (2.3%), peonidin

112

3-rutinoside (1.9%), cyanidin 3-rutinoside (1.8%), and cyanidin 3,5-diglucoside (1.3%) were also

113

detected at 520 nm. The quantitative analysis indicated that each mg of LCBP contains 0.37 mg

114

C3G and 0.23 mg EC.

115 116

2.2 Mouse paw edema model

117

The animal experimental protocol was drafted according to the guidelines of the Animal Care

118

and Use Committee of Kagoshima University (Permission N0. A12005). Male ICR mice (4 weeks

119

of age, Japan SLC Inc.) were group-housed under controlled light (12 h light/day) and temperature

120

(25℃), and free access to water and feed. After acclimatization for one week, the mice were

121

randomly divided into three groups (n=4): control, LPS, and LPS + LCBP. The mice in LPS +

122

LCBP group were orally administrated (p.o.) with 300 mg/kg BW of LCBP suspended in 0.1 ml

123

normal saline based on our pilot test, while other mice were administrated with 0.1 ml normal

124

saline only. After four days of pretreatment, paw edema was induced with LPS (1mg/kg BW) by

125

subcutaneous injection (s.c.) as described previously24. Mouse paw edema was determined by

126

measuring paw thickness with a digital caliper (model 19975, Shinwa Rules Co. Ltd, Japan)

127

before and every hour after LPS injection until 6 h.

128 129

2.3 Cytokine determination by multiplex technology in mouse serum

130

Serum levels of cytokines including interleukin (IL)-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6,

131

IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-17, eotaxin, granulocyte colony-stimulating factor

132

(G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN-γ, keratinocyte-


Page 6 of 44

Page 7 of 44


133

derived cytokine (KC), monocytes chemotactic protein-1 (MCP-1), macrophage inflammatory

134

protein (MIP)-1α, MIP-1β, RANTES, and tumor necrosis factor-α (TNF-α) in mouse sera were

135

measured with a Bio-Plex Pro Mouse Cytokine 23-Plex Panel kit (Bio-Rad Laboratories). The

136

assay was performed with a Bio-Plex machine (Bio-Plex 200 System, Bio-Rad, USA) according

137

to the manufacturer’s instruction, and the data were analyzed with the Bio-Plex manager software.

138 139

2.4 Cell culture and cytokine determination in culture medium

140

Mouse macrophage-like RAW264.7 cell line (Cell No. RCB0535, RIKEN Bio-Resource

141

Center Cell Bank, Tsukuba, Japan) was cultured in DMEM containing 10% FBS at 37 °C in a 5%

142

CO2 atmosphere. The cells were pre-cultured for 24 h and starved in serum-free media for 2.5 h to

143

eliminate the influence of FBS before treatment. To measure cytokines in culture media, the cells

144

were seeded into 6-well plates (5×105/well), and pretreated with LCBP for 30 min before exposure

145

to LPS for 12 h. The levels of IL-1β, IL-6, and TNF-α were measured by their respective ELISA

146

kits (Thermo Fisher Scientific Inc., IL, USA) according to the manufacturer’s manual.

147 148

2.5 Cell fractionation

149

To determine the expression of cell mediators of inflammation, RAW264.7 cells (1×106)

150

were pre-cultured in 6-cm dishes, and then treated with 75, 150, or 300 μg/ml of LCBP for 30 min

151

before exposure to LPS (40 ng/ml) for indicated times. Whole cell lysates were obtained by

152

ultrasonication in RIPA buffer. Nuclear protein extracts were prepared by a modified method

153

based on previous studies10, 25. In brief, the harvested cells were lysed on ice in buffer A [1 mM

154

dithiothreitol, 0.1 mM EDTA, 10 mM Hepes-KOH (pH 7.9), 10 mM KCl, 0.5% Nonidet P-40, and



155

0.5 mM phenylmethylsulfonyl fluoride] for 30 min. After being centrifuged at 13500 g (4 °C, 15

156

min), the nuclear pellets were washed with buffer A for three times and resuspended in buffer B [1

157

mM dithiothreitol, 1 mM EDTA, 20 mM Hepes (pH 7.9), 0.5 M KCl, and 1 mM

158

phenylmethylsulfonyl fluoride] on a rotating wheel for 30 min at 4 °C. The supernatants contain

159

nuclear proteins were obtained by centrifugation (13500 g, 4 °C, 15 min) and then analyzed by

160

Western blot assay.

161 162

2.6 Ex vivo pull-down assay

163

Ex vivo pull-down assay was performed as described in previous study24. Briefly, EC or C3G

164

(5 μM) were coupled to CNBr-activated Sepharose 4B beads (25 mg) overnight at 4 °C in a

165

coupling buffer [25% DMSO, 0.5 M NaCl, and 0.1 M NaHCO3 (pH 8.3)] according to the

166

manufacturer’s manual. After centrifugation (1000g, 4 °C, 3 min), the beads were washed with

167

coupling buffer (5 volumes) and then resuspended in 0.1 M Tris-HCl buffer (pH 8.0, 5 volumes)

168

for 2 h rotation. The conjugated beads were then washed with acetate buffer [0.1 M acetic acid

169

(pH 4.0) and 0.5 M NaCl] and wash buffer [0.5 M NaCl and 0.1 M Tris-HCl (pH 8.0)] for three

170

cycles. The RAW264.7 cell lysates (500 μg/mL) were then incubated with the EC or

171

C3G-conjugated beads (100 μL, 50% slurry), or control beads in a reaction buffer [2 μg/mL BSA,

172

1 mM dithiothreitol, 5 mM EDTA, 150 mM NaCl, 0.01% Nonidet P-40, 0.02 mM PMSF, 50 mM

173

Tris-HCl (pH 8.5), and 1 μg protease inhibitor cocktail] overnight at 4 °C. The bound lysates were

174

washed with the buffer containing 1 mM dithiothreitol, 5 mM EDTA, 200 mM NaCl, 0.02%

175

Nonidet P-40, 0.02 mM PMSF, and 50 mM Tris-HCl (pH 7.5) for five times, and the proteins

176

bound to the beads were analyzed by Western blot assay.


Page 8 of 44

Page 9 of 44


177 178

2.7 Western blot assay

179

Western blotting was performed as described previously10. Briefly, obtained protein extracts

180

were quantitated by protein assay and then boiled in SDS sample buffer for 5 min, and equal

181

amounts of protein (40 μg) were run on 10% SDS-PAGE followed by transfer to PVDF membrane.

182

After blocking, the membrane was incubated with specific primary antibody (4 °C, overnight) and

183

corresponding HRP-conjugated secondary antibody (room temperature, 1 h). The bound

184

antibodies were then detected by the ECL system with a Lumi Vision PRO machine (TAITEC Co.,

185

Saitama, Japan), and the relative amount of proteins was quantified by Lumi Vision Imager

186

software (TAITEC Co., Saitama, Japan).

187 188

2.8 Statistical analysis

189

Results are expressed as means ±SD. Significant differences were determined using one-way

190

ANOVA followed by Duncan’s Multiple Range test (SPSS19, IBM Corp., Armonk, NY, USA).

191

Protein expression was expressed as induction folds to that of control by densitometry. A

192

probability of P < 0.05 was considered significant.

193 194

3

195

3.1 The inhibitory effect of LCBP on LPS-induced paw edema

Results

196

Mouse paw edema experimental scheme was shown in Figure 1A, and the change in paw

197

thickness was shown in Figure 1B. The initial paw thicknesses of mice in each group were not

198

different, but injection of LPS (1 mg/kg BW) increased average paw thickness (n=4) from 2.7 to



199

3.3 mm at 1 h, and the paw swelling remained till the end (paw thickness=3.0 mm) in 6 h. Oral

200

administration of LCBP (300 mg/kg BW daily) for 4 days inhibited LPS-induced paw edema

201

significantly (P < 0.05). Particularly, the paw thickness was reduced from 3.3 to 3.1 mm at 1 h and

202

2.8 mm at 6 h. In comparing with LPS treatment alone, LCBP decreased the edema by 36.9% at 1

203

h, and 63.0% at 6 h, although the paw swelling was not completely disappeared within 6 h (Figure

204

1B). As a control, normal saline showed no effects on paw edema.

205 206

3.2 Modulation of serum cytokine levels by LCBP

207

To understand the regulatory effects of LCBP on the production of inflammatory cytokines,

208

we examined 23 kinds of cytokines in mouse serum simultaneously by multiplex assay as

209

described in Section 2. The results showed that injection of LPS induced more than fivefold

210

increase in serum levels of G-CSF, RANTES, MCP-1, KC, IL-10, MIP-1α, Eotaxin, IL-6, MIP-1β,

211

IL-1β, and IL-12(p40); more than twofold increase in the levels of IL-4, IL-9, IFN-γ, IL-1α, IL-13,

212

IL-12(p70), IL-2, and TNF-α; but less than twofold in the levels of GM-CSF, IL-3, IL-5, and

213

IL-17; comparing with that of mice without LPS injection (Figure 2). Oral administration of LCBP

214

at 300 mg/kg body weight significantly decreased (P < 0.05) the levels of RANTES, MCP-1, KC,

215

IL-10, MIP-1α, IL-6, IL-1β, IL-4, IL-12(p-70), IL-2, TNF-α, and IL-3, but showed no significant

216

effect (P > 0.05) on the levels of G-CSF, Eotaxin, MIP-1β, IL-12(p40), IL-9, IFN-γ, IL-1α, IL-13,

217

GM-CSF, IL-5, and IL-17. These results suggested that LCBP attenuated LPS-induced mouse paw

218

edema by reducing the production of multiple inflammatory cytokines.

219 220

3.3 Modulation of the MAPK pathway by LCBP


Page 10 of 44

Page 11 of 44


221

To further understand the regulatory effects of LCBP on cellular inflammatory pathways, we

222

next used a LPS-activated microphage (RAW264.7) cell model, which can mimic a situation of

223

infection. The production of representative IL-1β, IL-6, and TNF-α was first measured in the

224

culture media to confirm the anti-inflammatory effect of LCBP in the model. As shown in Figure

225

3A, the levels of IL-1β, IL-6, and TNF-α were significantly increased (P < 0.05) by LPS

226

stimulation, and concentration-dependently reduced by pretreatment with 75-300 μg/ml of LCBP.

227

Moreover, the expression of iNOS, another marker of LPS-induced inflammation, was also

228

decreased by pretreatment with LCBP (75-300 μg/ml) in the same manner (Figure 3B).

229

Accumulated data indicate that LPS can induce the activation of MAPKs including JNK,

230

ERK and p38 kinase, and subsequently activates transcription factors such as AP-1 to promote the

231

production of cytokines10. To investigate the cellular signaling pathways involved in the inhibition

232

of inflammatory mediators by LCBP, we first checked the phosphorylation of c-Jun, which is a

233

major component of AP-1 in c-Jun/c-Fos heterodimer form. The results showed that pretreatment

234

with 75-300 μg/ml of LCBP concentration-dependently inhibited LPS-induced c-jun

235

phosphorylation in RAW264.7 cells (Figure 4A). Correspondingly, pretreatment with LCBP also

236

suppressed the phosphorylation of JNK1/2, ERK1/2 and p38 kinase in the same manner (Figure

237

4B). These results suggested that down-regulation of MAPK pathways was involved in the

238

inhibition of inflammatory cytokines production by LCBP.

239 240

3.4 Modulation of the NF-κB pathway by LCBP

241

Since NF-κB is one of the major transcription factors to mediate the production of

242

inflammatory cytokines26, we next investigated the effects of LCBP on the translocation of NF-κB.



243

The results showed that LPS induced a fourfold increase in nuclear NF-κB p65, and pretreatment

244

with LCBP (300 μg/ml) reduced the nuclear translocation of p65 to 1.4 fold (Figure 5A). We

245

further confirmed that the phosphorylation of p65, IκB-α were also suppressed by pretreatment

246

with 75-300 μg/ml of LCBP in a concentration-dependent manner (Figure 5B). Correspondingly,

247

the total protein of IκB-α was decreased by LPS, and restored by LCBP. Moreover, the activation

248

of IKKα/β, an upstream kinase, was also suppressed by LCBP. Thus, LCBP potentially reduced

249

the production of inflammatory cytokines also by down-regulating NF-κB pathway.

250 251

3.5 Modulation of cellular antioxidant mediators by LCBP

252

Recent studies have shown that antioxidant mediators also play critical roles in counteracting

253

inflammatory response19. Thus, we investigated the effects of LPS and LCBP on the expression of

254

Nrf2 and MnSOD, two important antioxidant mediators, with a time-course experiment in

255

RAW264.7 cells. Our results showed that LPS induced more than threefold expression of Nrf2 and

256

MnSOD after 12 and 24h treatment (Figure 6A), and LCBP induced more than threefold

257

expression of MnSOD and Nrf2 from 6-24h (Figure 6B). However, the oxidative stress-response

258

proteins such as HSP70 and iNOS were induced only by LPS, not by LCBP. These results

259

suggested that LCBP might activate antioxidant response pathways early to counteract the

260

oxidative stress induced by LPS.

261

The major phenolic components of LCBP were identified as C3G and EC in our previous

262

study4. To know whether C3G and EC are the major biological modulators of LCBP, the

263

regulatory effects of C3G and EC on the inflammatory and antioxidant mediators were

264

investigated in LPS-activated RAW264.7 cells. As shown in Figure 7A, both EC (69 μg/ml) and


Page 12 of 44

Page 13 of 44


265

C3G (111 μg/ml) enhanced the expression of MnSOD and Nrf2, but decreased LPS-induced

266

expression of HSP70 and iNOS. Especially, the combination of EC and C3G, which is equal to the

267

amount in LCBP, showed similar effect as LCBP. Thus, C3G and EC of LCBP might be the major

268

modulators for these actions.

269

Since TAK1 is a key regulator of both MAPK and NF-κB pathways, we speculated that C3G

270

and EC of LCBP may target TAK1 to modulate the inflammatory mediators. Thus, we first

271

examined whether these components attenuate the TAK1 activation. As shown in Figure 7B, the

272

combination of C3G and EC effectively suppressed LPS-induced phosphorylation of TAK1 as

273

well as LCBP. Next, we examined whether C3G and EC directly bind to TAK1 to suppress TAK1

274

activation, using ex vivo pull-down assay as described in Section 2. As shown in Figure 7C, TAK1

275

was detected in the beads coupled with EC (51.9% binding rate) or C3G (38.6% binding rate), but

276

not in the beads alone (Figure 7C). These data demonstrated that C3G and EC might directly bind

277

to TAK1 to attenuate the activation.

278 279 280 281

4

Discussion The present study demonstrated that LCBP inhibited LPS-induced inflammation by dually

modulating inflammatory and antioxidant mediators.

282

Although inflammatory and antioxidant mediators are complicated, cytokines and

283

Nrf2-activated antioxidant mediators are critical mediators in inflammatory response19, 27. In this

284

study, we first used mouse paw edema model induced by LPS, which is a strong inducer for

285

cytokine production and significantly increased serum levels of 21 kinds of cytokines except IL-5

286

and IL-17. Oral administration of LCBP significantly reduced serum levels of 12 kinds of which



287

including RANTES, MCP-1, KC, IL-10, MIP-1α, IL-6, IL-1β, IL-4, IL-12(p-70), IL-2, TNF-α,

288

and IL-3. Among these cytokines, IL-10 and IL-4 are considered as anti-inflammatory cytokines

289

against excessive inflammation and self-immunity28. IL-6, IL-1β, IL-12(p-70), IL-2, and TNF-α

290

are the initially modulated cytokines, since RANTES can be regulated by TNF-α29, MCP-1 is one

291

of the downstream targets of IL-630, and IL-1β can induce the expression of KC, MIP-1α, and

292

MIP-1β31, 32. On the other hand, LPS also can activate oxidative stress response pathways in

293

macrophages19. For example, LPS can activate NADPH oxidase through TLR4 leading to the

294

excessive production of superoxide radicals (O2·-) and subsequent hydrogen peroxide (H2O2)33.

295

These excessive products cause NF-κB-mediated inflammatory response34, and simultaneously

296

activate Nrf2-mediated oxidative stress response pathway to counteract the reactive oxygen

297

species35. In the present study, increased levels of both antioxidant response proteins (Nrf2 and

298

MnSOD) and oxidative stress markers (HSP70 and iNOS) were observed in LPS-activated

299

RAW264.7 cells. LCBP also increased the expression of Nrf2 and MnSOD, but not HSP70 and

300

iNOS. The time-course experiments revealed that the induction time of Nrf2 and MnSOD

301

expression by LCBP was from 6 h, which was earlier than from 12 h by LPS. These data

302

suggested that LCBP might activate antioxidant response pathways early to counteract the

303

oxidative stress induced by LPS. Several lines of studies have demonstrated the expression level

304

of Nrf2 is correlated with inflammatory pathways, in which, knockdown of Nrf2 promoted the

305

expression of NF-κB-mediated inflammatory pathways34, 36. Thus, our data suggested that LCBP

306

primarily activated Nrf2-mediated oxidative stress response pathways to counteract LPS-induced

307

reactive oxygen species, and further prevent against LPS-induced inflammation.

308

In this study, we found that LCBP inhibited TLR4-mediated inflammation by down-


Page 14 of 44

Page 15 of 44


309

regulating both MAPK and NF-κB pathways. Thus, we speculated that TAK1 might be a target

310

molecule for LCBP-inhibited inflammatory signaling since TAK1 is a common upstream kinase

311

that activated by TLR4. The ex vivo binding data revealed that C3G and EC, two major active

312

compounds of LCBP, could directly bind to TAK1, and inhibit its phosphorylation. These data

313

suggested that TAK1 might be the primary target for suppressing inflammatory mediator

314

activation by LCBP. On the other hand, we previously identified MEK1 as a binding target to

315

delphinidin or its glycoside Dp-3-sam37, analogues of cyanidin or C3G. Thus cannot exclude the

316

possibility that C3G and/or EC may target other cellular kinases to exert their biological activity,

317

which is valuable to be investigated in further work.

318

The effective concentrations of C3G and EC in cell experiments in this study were over 50

319

μM, which are similar to the effective concentrations of other polyphenols such as other

320

anthocyanidins10 and tea proanthocyanidins38 as reported previously. Accumulated data have

321

shown that the effective concentrations of polyphenols in culture cells are, in general, quite higher

322

than those measured in animal tissue or plasma. Although it is still hard to fill the gap between the

323

two, some lines of studies have indicated that cells cultured under laboratory conditions of 95%

324

air/5% CO2 are in a state of hyperoxia, experiencing about 150 mmHg of O2, whereas most cells

325

in the human body are exposed to O2 concentrations in the range of 1-10 mmHg 39. Polyphenols in

326

higher O2 concentration tend to be broken down 40. Another reason is that most polyphenols can

327

bind to bovine serum albumin (BSA) in cultural medium and form polyphenols-BSA complex41,

328

which reduced free polyphenols amount for action. Therefore, the effective concentrations of C3G

329

and EC to reach the targeting molecules might be quite lower than that at addition in cultural cells.

330

These facts can partially explain why most polyphenols show the effects in culture cells with



Page 16 of 44

331

higher concentrations than in animal serum, and suggest that the concentration of polyphenols in

332

cell culture could not be simply considered as the concentration in animal serum or tissues.

333

Most animal and human studies have found that anthocyanins present in natural food source

334

were absorbed mainly in their intact glycosidic form42, 43 from the stomach after ingestion by a

335

process that may involve bilitranslocase44, while EC could be absorbed as its original form45.

336

Therefore, the major active compounds, C3G and EC might exert the anti-inflammatory function

337

partially as the structures at absorption. It is also reported that C3G could be degraded into

338

phenolic metabolites such as protocatechuic acid, phloroglucinaldehyde, and ferulic acid46, which

339

may act as bioactive molecules. The biological activities of these metabolites after absorption will

340

be investigated in our coming work.

341

The phenolic components of LCBP were analyzed by HPLC in our previous study, and the

342

major components were identified as C3G and EC4. Other studies also suggested that C3G is the

343

major anthocyanin in Lonicera caerulea L. berry 1, 47-49, while the concentration of EC is diverse

344

in different cultivars1, 48, 50. Although other minor anthocyanins including peonidin 3-glucoside,

345

pelargonidin

346

3,5-diglucoside were also contained in LCBP according to HPLC analysis, peonidin and

347

pelargonidin showed limited effects on LPS-induced inflammation in our previous study

348

Cyanidin 3-rutinoside and cyanidin 3,5-diglucoside might have potential bioactive effects against

349

inflammatory factors and oxidative stress

350

effective concentration. Thus, C3G and EC are considered as the major biological modulators of

351

LCBP for antioxidant and inflammatory activities.

352

3-glucoside,

peonidin

3-rutinoside,

cyanidin

3-rutinoside,

and

cyanidin

10

.

51, 52

, but their contents in LCBP were far below the

Taken together, LCBP, rich in C3G and EC, inhibited LPS-induced inflammation through the


Page 17 of 44


353

dual modulation of inflammatory and antioxidant mediators, reducing the production of multiple

354

inflammatory cytokines and enhancing the expression of Nrf2 and MnSOD. These findings

355

provided a comprehensive understanding of the anti-inflammatory property of LCBP at the

356

molecular level.

357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374



375

Abbreviations used: C3G, cyanidin 3-glucoside; EC, -(-)epicatechin; ERK, extracellular

376

signal-regulated kinase; HSP70, 70-kDa heat shock protein; IKK, IκB kinases; IL, interleukin;

377

iNOS, inducible nitric oxide synthases; JNK, c-Jun N-terminal kinase; KC, keratinocyte-derived

378

cytokine; LPS, lipopolysaccharide; LCBP, Lonicera caerulea L. berry polyphenols; MAPK,

379

mitogen-activated protein kinase; MCP-1, monocytes chemotactic protein-1; MIP, macrophage

380

inflammatory protein; MnSOD, manganese-dependent superoxide dismutase; NF-κB, nuclear

381

factor-κB; Nrf2, nuclear factor (erythroid-derived 2)-like 2; TAK1, transforming growth factor β

382

activated kinase-1; TNF-α, tumor necrosis factor-α

383 384

Conflict of interest

385

The authors have declared no conflict of interest.

386 387

Funding sources

388

This work was partially supported by the funds from Core Research Program 1515 and Hunan

389

Collaborative Innovation Center for Utilization of Botanical Functional Ingredients of Hunan

390

Agricultural University, China, and by the funds from the Scholar Research of Kagoshima

391

University, Japan (D.X. Hou).

392 393 394 395 396


Page 18 of 44

Page 19 of 44


397

References

398

1.

399

F.; Hola, V.; Kolar, M.; Simanek, V.; Ulrichova, J., Constituents and antimicrobial properties of

400

blue honeysuckle: a novel source for phenolic antioxidants. J. Agric. Food Chem. 2008, 56,

401

11883-9.

402

2.

403

against oxidative human endothelial cells and rat hepatocyte damage. J. Agric. Food Chem. 2009,

404

57, 6584-9.

405

3.

406

Polyphenolic fraction of Lonicera caerulea L. fruits reduces oxidative stress and inflammatory

407

markers induced by lipopolysaccharide in gingival fibroblasts. Food Chem. Toxicol. 2010, 48,

408

1555-61.

409

4.

410

honeysuckle (Lonicera caerulea L) on adjuvant-induced arthritis in rats: Crosstalk of

411

anti-inflammatory and antioxidant effects. J. Funct. Foods 2015, 17, 514-523.

412

5.

413

Lonicera caerulea L. berry attenuate experimental nonalcoholic steatohepatitis by inhibiting

414

proinflammatory cytokines productions and lipid peroxidation. Mol. Nutr. Food Res. 2016.

415

6.

416

LPS-induced cytokine production in human monocytes and macrophages. Crit. Rev. Immunol.

417

2011, 31, 379-446.

418

7. Kanda, H.; Tateya, S.; Tamori, Y.; Kotani, K.; Hiasa, K.; Kitazawa, R.; Kitazawa, S.; Miyachi,

Palikova, I.; Heinrich, J.; Bednar, P.; Marhol, P.; Kren, V.; Cvak, L.; Valentova, K.; Ruzicka,

Palikova, I.; Valentova, K.; Oborna, I.; Ulrichova, J., Protectivity of blue honeysuckle extract

Zdarilova, A.; Rajnochova Svobodova, A.; Chytilova, K.; Simanek, V.; Ulrichova, J.,

Wu, S.; He, X.; Wu, X.; Qin, S.; He, J.; Zhang, S.; Hou, D.-X., Inhibitory effects of blue

Wu, S.; Yano, S.; Hisanaga, A.; He, X.; He, J.; Sakao, K.; Hou, D. X., Polyphenols from

Rossol, M.; Heine, H.; Meusch, U.; Quandt, D.; Klein, C.; Sweet, M. J.; Hauschildt, S.,



419

H.; Maeda, S.; Egashira, K.; Kasuga, M., MCP-1 contributes to macrophage infiltration into

420

adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. 2006, 116,

421

1494-505.

422

8.

423

phosphatases: manipulating MAP kinase signalling and immune responses. Nat. Rev. Drug Discov.

424

2007, 6, 391-403.

425

9.

426

Liu, L.; Chen, S.; Shao, F., Cysteine methylation disrupts ubiquitin-chain sensing in NF-kappaB

427

activation. Nature 2012, 481, 204-8.

428

10. Hou, D. X.; Yanagita, T.; Uto, T.; Masuzaki, S.; Fujii, M., Anthocyanidins inhibit

429

cyclooxygenase-2 expression in LPS-evoked macrophages: structure-activity relationship and

430

molecular mechanisms involved. Biochem. Pharmacol. 2005, 70, 417-25.

431

11. Baeuerle, P.; Baltimore, D., I kappa B: a specific inhibitor of the NF-kappa B transcription

432

factor. Science 1988, 242, 540-546.

433

12. Traenckner, E. B.; Pahl, H. L.; Henkel, T.; Schmidt, K. N.; Wilk, S.; Baeuerle, P. A.,

434

Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha

435

proteolysis and NF-kappa B activation in response to diverse stimuli. The EMBO Journal 1995, 14,

436

2876-2883.

437

13. Viatour, P.; Merville, M. P.; Bours, V.; Chariot, A., Phosphorylation of NF-kappaB and

438

IkappaB proteins: implications in cancer and inflammation. Trends Biochem. Sci. 2005, 30, 43-52.

439

14. Israel, A., The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb.

440

Perspect. Biol. 2010, 2, a000158.

Jeffrey, K. L.; Camps, M.; Rommel, C.; Mackay, C. R., Targeting dual-specificity

Zhang, L.; Ding, X.; Cui, J.; Xu, H.; Chen, J.; Gong, Y. N.; Hu, L.; Zhou, Y.; Ge, J.; Lu, Q.;


Page 20 of 44

Page 21 of 44


441

15. Ajibade, A. A.; Wang, H. Y.; Wang, R. F., Cell type-specific function of TAK1 in innate

442

immune signaling. Trends Immunol. 2013, 34, 307-16.

443

16. Kawai, T.; Akira, S., TLR signaling. Cell Death Differ. 2006, 13, 816-25.

444

17. Borovikova, L. V.; Ivanova, S.; Zhang, M.; Yang, H.; Botchkina, G. I.; Watkins, L. R.; Wang,

445

H.; Abumrad, N.; Eaton, J. W.; Tracey, K. J., Vagus nerve stimulation attenuates the systemic

446

inflammatory response to endotoxin. Nature 2000, 405, 458-462.

447

18. Medzhitov, R., Origin and physiological roles of inflammation. Nature 2008, 454, 428-35.

448

19. Mo, C.; Wang, L.; Zhang, J.; Numazawa, S.; Tang, H.; Tang, X.; Han, X.; Li, J.; Yang, M.;

449

Wang, Z.; Wei, D.; Xiao, H., The crosstalk between Nrf2 and AMPK signal pathways is important

450

for

451

endotoxin-shocked mice. Antioxid. Redox. Signal. 2014, 20, 574-88.

452

20. Becuwe, P.; Ennen, M.; Klotz, R.; Barbieux, C.; Grandemange, S., Manganese superoxide

453

dismutase in breast cancer: from molecular mechanisms of gene regulation to biological and

454

clinical significance. Free Radic. Biol. Med. 2014, 77, 139-51.

455

21. Ishihara, Y.; Takemoto, T.; Itoh, K.; Ishida, A.; Yamazaki, T., Dual role of superoxide

456

dismutase 2 induced in activated microglia: oxidative stress tolerance and convergence of

457

inflammatory responses. J. Biol. Chem. 2015, 290, 22805-17.

458

22. Rushworth, S. A.; Chen, X. L.; Mackman, N.; Ogborne, R. M.; O'Connell, M. A.,

459

Lipopolysaccharide-induced heme oxygenase-1 expression in human monocytic cells is mediated

460

via Nrf2 and protein kinase C. J. Immunol. 2005, 175, 4408-15.

461

23. Rönnblom, L.; Elkon, K. B., Cytokines as therapeutic targets in SLE. Nat. Rev. Rheumatol.

462

2010, 6, 339-347.

the

anti-inflammatory

effect

of

berberine

in

LPS-stimulated


macrophages

and


Page 22 of 44

463

24. Hisanaga, A.; Mukai, R.; Sakao, K.; Terao, J.; Hou, D. X., Anti-inflammatory effects and

464

molecular mechanisms of 8-prenyl quercetin. Mol. Nutr. Food Res. 2016, 60, 1020-32.

465

25. Hou, D. X.; Korenori, Y.; Tanigawa, S.; Yamada-Kato, T.; Nagai, M.; He, X.; He, J.,

466

Dynamics

467

6-(methylsulfinyl)hexyl isothiocyanate. J. Agric. Food Chem. 2011, 59, 11975-82.

468

26. Tak, P. P.; Firestein, G. S., NF-κB: a key role in inflammatory diseases. J. Clin. Invest. 2001,

469

107, 7-11.

470

27. Brennan, F. M.; McInnes, I. B., Evidence that cytokines play a role in rheumatoid arthritis. J.

471

Clin. Invest. 2008, 118, 3537-45.

472

28. Woodward, E. A.; Kolesnik, T. B.; Nicholson, S. E.; Prêle, C. M.; Hart, P. H., The

473

anti-inflammatory actions of IL-4 in human monocytes are not mediated by IL-10, RP105 or the

474

kinase activity of RIPK2. Cytokine 2012, 58, 415-423.

475

29. Hirano, F.; Komura, K.; Fukawa, E.; Makino, I., Tumor necrosis factor α (TNF-α)-induced

476

RANTES chemokine expression via activation of NF-κB and p38 MAP kinase: roles of TNF-α in

477

alcoholic liver diseases. J. Hepatol. 2003, 38, 483-489.

478

30. Atreya, R.; Mudter, J.; Finotto, S.; Mullberg, J.; Jostock, T.; Wirtz, S.; Schutz, M.; Bartsch, B.;

479

Holtmann, M.; Becker, C.; Strand, D.; Czaja, J.; Schlaak, J. F.; Lehr, H. A.; Autschbach, F.;

480

Schurmann, G.; Nishimoto, N.; Yoshizaki, K.; Ito, H.; Kishimoto, T.; Galle, P. R.; Rose-John, S.;

481

Neurath, M. F., Blockade of interleukin 6 trans signaling suppresses T-cell resistance against

482

apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis

483

in vivo. Nat. Med. 2000, 6, 583-588.

484

31. Gamero, A. M.; Oppenheim, J. J., IL-1 can act as number one. Immunity 2006, 24, 16-7.

of

Nrf2

and

Keap1

in

ARE-mediated

NQO1


expression

by

wasabi

Page 23 of 44


485

32. Guo, C.-J.; Douglas, S. D.; Lai, J.-P.; Pleasure, D. E.; Li, Y.; Williams, M.; Bannerman, P.;

486

Song, L.; Ho, W.-Z., Interleukin-1β stimulates macrophage inflammatory protein-1α and -1β

487

expression in human neuronal cells (NT2-N). J. Neurochem. 2003, 84, 997-1005.

488

33. Panday, A.; Sahoo, M. K.; Osorio, D.; Batra, S., NADPH oxidases: an overview from

489

structure to innate immunity-associated pathologies. Cell. Mol. Immunol. 2014, 12, 5-23.

490

34. Li, W.; Khor, T. O.; Xu, C.; Shen, G.; Jeong, W. S.; Yu, S.; Kong, A. N., Activation of

491

Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis.

492

Biochem. Pharmacol. 2008, 76, 1485-9.

493

35. Purdom-Dickinson, S. E.; Sheveleva, E. V.; Sun, H.; Chen, Q. M., Translational control of

494

nrf2 protein in activation of antioxidant response by oxidants. Mol. Pharmacol. 2007, 72,

495

1074-81.

496

36. Khor, T. O.; Huang, M. T.; Kwon, K. H.; Chan, J. Y.; Reddy, B. S.; Kong, A. N.,

497

Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis.

498

Cancer Res. 2006, 66, 11580-4.

499

37. Sogo, T.; Kumamoto, T.; Ishida, H.; Hisanaga, A.; Sakao, K.; Terahara, N.; Wada, K.; Hou, D.

500

X., Comparison of the inhibitory effects of delphinidin and its glycosides on cell transformation.

501

Planta Med. 2015, 81, 26-31.

502

38. Hou, D. X.; Luo, D.; Tanigawa, S.; Hashimoto, F.; Uto, T.; Masuzaki, S.; Fujii, M.; Sakata, Y.,

503

Prodelphinidin B-4 3'-O-gallate, a tea polyphenol, is involved in the inhibition of COX-2 and

504

iNOS via the downregulation of TAK1-NF-kappaB pathway. Biochem. Pharmacol. 2007, 74,

505

742-51.

506

39. Tang, S. Y.; Halliwell, B., Medicinal plants and antioxidants: what do we learn from cell



507

culture and Caenorhabditis elegans studies? Biochem. Biophys. Res. Commun. 2010, 394, 1-5.

508

40. Halliwell, B., Oxidative stress in cell culture: an under-appreciated problem? FEBS Lett.

509

2003, 540, 3-6.

510

41. Dufour, C.; Dangles, O., Flavonoid-serum albumin complexation: determination of binding

511

constants and binding sites by fluorescence spectroscopy. Biochim. Biophys. Acta 2005, 1721,

512

164-73.

513

42. Miyazawa, T.; Nakagawa, K.; Kudo, M.; Muraishi, K.; Someya, K., Direct intestinal

514

absorption of red fruit anthocyanins, cyanidin-3-glucoside and cyanidin-3,5-diglucoside, into rats

515

and humans. J. Agric. Food Chem. 1999, 47, 1083-91.

516

43. McGhie, T. K.; Ainge, G. D.; Barnett, L. E.; Cooney, J. M.; Jensen, D. J., Anthocyanin

517

glycosides from berry fruit are absorbed and excreted unmetabolized by both humans and rats. J.

518

Agric. Food Chem. 2003, 51, 4539-48.

519

44. Fernandes, I.; Marques, F.; de Freitas, V.; Mateus, N., Antioxidant and antiproliferative

520

properties of methylated metabolites of anthocyanins. Food Chem. 2013, 141, 2923-33.

521

45. Baba, S.; Osakabe, N.; Natsume, M.; Muto, Y.; Takizawa, T.; Terao, J., Absorption and

522

Urinary Excretion of (−)-Epicatechin after Administration of Different Levels of Cocoa Powder or

523

(−)-Epicatechin in Rats. J. Agric. Food Chem. 2001, 49, 6050-6056.

524

46. Amin, H. P.; Czank, C.; Raheem, S.; Zhang, Q.; Botting, N. P.; Cassidy, A.; Kay, C. D.,

525

Anthocyanins and their physiologically relevant metabolites alter the expression of IL-6 and

526

VCAM-1 in CD40L and oxidized LDL challenged vascular endothelial cells. Mol. Nutr. Food Res.

527

2015, 59, 1095-106.

528

47. Chaovanalikit, A.; Thompson, M. M.; Wrolstad, R. E., Characterization and quantification of


Page 24 of 44

Page 25 of 44


529

anthocyanins and polyphenolics in bluehHoneysuckle (Lonicera caerulea L.). J. Agric. Food Chem.

530

2004, 52, 848-52.

531

48. Oszmiański, J.; Wojdyło, A.; Lachowicz, S., Effect of dried powder preparation process on

532

polyphenolic content and antioxidant activity of blue honeysuckle berries (Lonicera caerulea L.

533

var. kamtschatica). LWT - Food Science and Technology 2016, 67, 214-222.

534

49. Kusznierewicz, B.; Piekarska, A.; Mrugalska, B.; Konieczka, P.; Namiesnik, J.; Bartoszek, A.,

535

Phenolic composition and antioxidant properties of Polish blue-berried honeysuckle genotypes by

536

HPLC-DAD-MS, HPLC postcolumn derivatization with ABTS or FC, and TLC with DPPH

537

visualization. J. Agric. Food Chem. 2012, 60, 1755-63.

538

50. Rupasinghe, H. P.; Boehm, M. M.; Sekhon-Loodu, S.; Parmar, I.; Bors, B.; Jamieson, A. R.,

539

Anti-Inflammatory Activity of Haskap Cultivars is Polyphenols-Dependent. Biomolecules 2015, 5,

540

1079-98.

541

51. Youdim, K. A.; Martin, A.; Joseph, J. A., Incorporation of the elderberry anthocyanins by

542

endothelial cells increases protection against oxidative stress1. Free Radic. Biol. Med. 2000, 29,

543

51-60.

544

52. Chen, P. N.; Chu, S. C.; Chiou, H. L.; Kuo, W. H.; Chiang, C. L.; Hsieh, Y. S., Mulberry

545

anthocyanins, cyanidin 3-rutinoside and cyanidin 3-glucoside, exhibited an inhibitory effect on the

546

migration and invasion of a human lung cancer cell line. Cancer Lett. 2006, 235, 248-59.

547 548 549 550



551

Figure captions

552 553

Figure 1

554

experimental procedure of mouse paw edema model. ICR mice were randomly divided into three

555

groups (n=4): control (CTL), LPS, and LPS+LCBP. Mice were orally administrated (p.o.) with

556

LCBP (300 mg/kg BW daily) for 4 days, and LPS (1mg/kg) was then injected subcutaneously (s.c.)

557

into mouse paw. Paw thickness was measured before and every hour after LPS injection until 6 h.

558

(B) The change in paw thickness. The data represent mean ± SD, and values with different

559

superscript letters differ significantly (P < 0.05), the superscript b represents significant difference

560

with CTL group (a), while c represents significant difference with LPS group (b).

The inhibitory effect of LCBP on LPS-induced mouse paw edema. (A) The

561 562

Figure 2

563

obtained from the mice 6 h after LPS injection. Serum levels of 23 kinds of cytokines were

564

measured by multiplex technology, and arranged in an order from high to low change in

565

LPS-induced mice. The data represent mean ± SD, and values with different superscript letters

566

differ significantly (P < 0.05), the superscript b represents significant difference with CTL group

567

(a), while c represents significant difference with LPS group (b).

Modulation of serum cytokine levels by LCBP. The blood sera of mice were

568 569

Figure 3 The inhibitory effect of LCBP on the production of IL-1β, IL-6, TNF-α, and iNOS

570

in LPS-activated RAW264.7cells. The cells were treated with 75, 150, or 300 μg/ml of LCBP for

571

30 min and then exposed to LPS (40 ng/ml) for 12 h. (A) The levels of IL-1β, IL-6, and TNF-α in

572

culture media. The data represent mean ± SD of six repeats, and values with different superscript


Page 26 of 44

Page 27 of 44


573

letters differ significantly (P < 0.05), the superscript b represents significant difference with

574

normal cells (a), while c or d represents significant difference with LPS-activated cells (b). (B)

575

The total protein of iNOS in whole cell lysates by Western blotting. The induction fold of iNOS

576

protein was calculated as the intensity of the treatment relative to that of control normalized to

577

-tubulin by densitometry. The blots shown are the examples of three independent experiments.

578 579

Figure 4

580

150, or 300 μg/ml of LCBP for 30 min and then exposed to LPS (40 ng/ml) for another 30 min. (A)

581

The total and phosphorylated proteins of c-Jun, and (B) MAPKs including JNK1/2, ERK1/2, and

582

p38 kinase in whole cell lysates. The induction folds of the phosphorylated proteins were

583

calculated as the intensity of the treatment relative to that of control normalized to total proteins

584

by densitometry. The blots shown are the examples of three independent experiments.

Modulation of the MAPK pathway by LCBP. RAW264.7 cells were treated with 75,

585 586

Figure 5 Modulation of the NF-κB pathway by LCBP. Cell treatment was same as in Figure 4.

587

(A) The total protein of p65 in nuclear fraction. (B) The total and phosphorylated proteins of p65,

588

IκB-α, and IKKα/β in whole cell lysates. The induction folds were calculated as the intensity of

589

the treatment relative to that of control normalized to Lamin B (for nuclear p65), α-tubulin (for

590

IκB-α and p-IκB-α), or respective total proteins (for p-p65 and p-IKKα/β) by densitometry. The

591

blots shown are the examples of three independent experiments.

592 593

Figure 6

594

HSP70, and iNOS. RAW264.7 cells were treated with 40 ng/ml of LPS (A) or 300 μg/ml of

Time-course experiments of LPS and LCBP-induced expression of Nrf2, MnSOD,



595

LCBP (B) for 0.5-24 h. The total proteins of Nrf2, MnSOD, HSP70, and iNOS in whole cell

596

lysates were detected by Western blotting. Induction folds of the proteins were calculated as the

597

intensity of the treatment relative to that of control normalized to α-tubulin by densitometry. The

598

blots shown are the examples of three independent experiments.

599 600

Figure 7 Modulation of inflammatory and antioxidant mediators by LCBP, EC and C3G.

601

(A) The total proteins of Nrf2, MnSOD, HSP70, and iNOS in whole cell lysates. RAW264.7 cells

602

were treated with EC (69 μg/ml), C3G (111 μg/ml) or LCBP (300 μg/ml) for 30 min, and then

603

exposed to LPS (40 ng/ml) for 12 h. (B) The phosphorylated protein of TAK1 in whole cell lysates.

604

Cells were treated with EC, C3G or LCBP for 30 min, and then exposed to LPS for another 30

605

min. (C) The binding abilities of EC and C3G to TAK1 protein. The ex vivo pull-down assay was

606

performed as described in Section 2.6. The binding efficiency of EC or C3G to TAK1 protein was

607

presented as the ratio of input control (lane 1). The blots shown are the examples of three

608

independent experiments.

609 610 611 612 613 614 615 616


Page 28 of 44

Page 29 of 44

617


Figure 1

618 619 620 621 622 623 624 625 626 627



628

Figure 2

629


Page 30 of 44

Page 31 of 44

630


Figure 3

631 632



633

Figure 4

634 635 636 637 638 639


Page 32 of 44

Page 33 of 44

640


Figure 5

641 642 643 644



645

Figure 6

646 647 648 649


Page 34 of 44

Page 35 of 44

650


Figure 7

651 652 653 654 655 656



657

Table of Contents Graphic

658

659


Page 36 of 44

Page 37 of 44


218x201mm (300 x 300 DPI)



285x484mm (300 x 300 DPI)


Page 38 of 44

Page 39 of 44


177x293mm (300 x 300 DPI)



178x218mm (300 x 300 DPI)


Page 40 of 44

Page 41 of 44


176x242mm (300 x 300 DPI)



179x243mm (300 x 300 DPI)


Page 42 of 44

Page 43 of 44


221x273mm (300 x 300 DPI)



249x153mm (96 x 96 DPI)


Page 44 of 44

Polyphenols from Lonicera caerulea L. Berry ... - ACS Publications

Recommend Documents